Top Markets
#1 Official Trump Official Trump +46.28%
#2 Mubarak Mubarak +27.48%
#3 POL (ex-MATIC) POL (ex-MATIC) +22.48%
#4 Wrapped POL Wrapped POL +22.47%
#5 Melania Meme Melania Meme +19.93%
#6 Movement Movement +19.15%
#7 EXOD EXOD +18.93%
#8 Pearl Pearl +17.85%
#9 Wrapped STX (Velar) Wrapped STX (Velar) +16.27%
#10 Audiera Audiera +10.87%
Coin of the day
Official Trump Official Trump
Settings
Language
ENGLISH
Currency
USD
Theme
Citius Oncology, Inc. Citius Oncology, Inc.

Citius Oncology, Inc.

CTOR
Rank in Stocks #23802
Citius Oncology, Inc. concentrates on advancing innovative, targeted... Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.
Share Price
$0.7426
Last synced: 2026-08-21
Market Cap
$69.05M
Change (1 day)
-2.17%
Change (1 year)
-57.57%
Country
US
Trade Citius Oncology, Inc. (CTOR)

Category

Healthcare
Earnings for Citius Oncology, Inc. (CTOR)
Earnings in 2026 TTM: 0
According to Citius Oncology, Inc. latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Citius Oncology, Inc. from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
$33.59B -
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
$25.20B -
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
$8.70B -
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
$21.39B -
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
$5.95B -
US